Wei Li1, Jing Qin, Yi-Hong Sun, Tian-Shu Liu. 1. Department of Medical Oncology, Shanghai Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai 200032, China.
Abstract
AIM: To study the value of neoadjuvant chemotherapy (NAC) for advanced gastric cancer by performing a meta-analysis of the published studies. METHODS: All published controlled trials of NAC for advanced gastric cancer vs no therapy before surgery were searched. Studies that included patients with metastases at enrollment were excluded. Databases included Cochrane Library of Clinical Comparative Trials, MEDLINE, Embase, and American Society of Clinical Oncology meeting abstracts from 1978 to 2010. The censor date was up to April 2010. Primary outcome was the odds ratio (OR) for improving overall survival rate of patients with advanced gastric cancer. Secondary outcome was the OR for down-staging tumor and increasing R0 resection in patients with advanced gastric cancer. Safety analyses were also performed. All calculations and statistical tests were performed using RevMan 5.0 software. RESULTS: A total of 2271 patients with advanced gastric cancer enrolled in 14 trials were divided into NAC group (n = 1054) and control group (n = 1217). The patients were followed up for a median time of 54 mo. NAC significantly improved the survival rate [OR = 1.27, 95% confidence interval (CI): 1.04-1.55], tumor stage (OR = 1.71, 95% CI: 1.26-2.33) and R0 resection rate (OR = 1.51, 95% CI: 1.19-1.91) of patients with advanced gastric cancer. No obvious safety concerns were raised in these trials. CONCLUSION: NAC can improve tumor stage and survival rate of patients with advanced gastric cancer with a rather good safety.
AIM: To study the value of neoadjuvant chemotherapy (NAC) for advanced gastric cancer by performing a meta-analysis of the published studies. METHODS: All published controlled trials of NAC for advanced gastric cancer vs no therapy before surgery were searched. Studies that included patients with metastases at enrollment were excluded. Databases included Cochrane Library of Clinical Comparative Trials, MEDLINE, Embase, and American Society of Clinical Oncology meeting abstracts from 1978 to 2010. The censor date was up to April 2010. Primary outcome was the odds ratio (OR) for improving overall survival rate of patients with advanced gastric cancer. Secondary outcome was the OR for down-staging tumor and increasing R0 resection in patients with advanced gastric cancer. Safety analyses were also performed. All calculations and statistical tests were performed using RevMan 5.0 software. RESULTS: A total of 2271 patients with advanced gastric cancer enrolled in 14 trials were divided into NAC group (n = 1054) and control group (n = 1217). The patients were followed up for a median time of 54 mo. NAC significantly improved the survival rate [OR = 1.27, 95% confidence interval (CI): 1.04-1.55], tumor stage (OR = 1.71, 95% CI: 1.26-2.33) and R0 resection rate (OR = 1.51, 95% CI: 1.19-1.91) of patients with advanced gastric cancer. No obvious safety concerns were raised in these trials. CONCLUSION:NAC can improve tumor stage and survival rate of patients with advanced gastric cancer with a rather good safety.
Authors: Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani Journal: J Clin Oncol Date: 2006-11-01 Impact factor: 44.544
Authors: Y Yonemura; T Sawa; K Kinoshita; N Matsuki; S Fushida; S Tanaka; S Ohoyama; T Takashima; H Kimura; T Kamata Journal: World J Surg Date: 1993 Mar-Apr Impact factor: 3.352
Authors: David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua Journal: N Engl J Med Date: 2006-07-06 Impact factor: 91.245
Authors: John M Creasy; Debra A Goldman; Vikas Dudeja; Maeve A Lowery; Andrea Cercek; Vinod P Balachandran; Peter J Allen; Ronald P DeMatteo; T Peter Kingham; Michael I D'Angelica; William R Jarnagin Journal: J Am Coll Surg Date: 2017-02-13 Impact factor: 6.113
Authors: Haejin In; Ethan Ravetch; Marisa Langdon-Embry; Bryan Palis; Jaffer A Ajani; Wayne L Hofstetter; David P Kelsen; Takeshi Sano Journal: Gastric Cancer Date: 2017-09-25 Impact factor: 7.370
Authors: Alberto Biondi; Maria C Lirosi; Domenico D'Ugo; Valeria Fico; Riccardo Ricci; Francesco Santullo; Antonia Rizzuto; Ferdinando Cm Cananzi; Roberto Persiani Journal: World J Gastrointest Oncol Date: 2015-12-15
Authors: John M Creasy; Debra A Goldman; Mithat Gonen; Vikas Dudeja; Gokce Askan; Olca Basturk; Vinod P Balachandran; Peter J Allen; Ronald P DeMatteo; Michael I D'Angelica; William R Jarnagin; T Peter Kingham Journal: J Gastrointest Surg Date: 2017-05-08 Impact factor: 3.452